Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ALMS

Alumis Inc

Apr 10 • 04:00PM ET

23.05

+0.11 0.48 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD REGN VRTX BIIB MRNA INCY BMY ABBV PFE

| Held by: VTI IWM VXF IWN IBB SCHA VTWO VHT FESM XPH

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.00	Insider Own	41.36%	Shs Outstand	99.08M	Perf Week	-1.37%
Market Cap	2.93B	Forward P/E	-	EPS next Y	-2.88	Insider Trans	10.11%	Shs Float	74.59M	Perf Month	-12.49%
Enterprise Value	2.66B	PEG	-	EPS next Q	-0.77	Inst Own	45.09%	Short Float	15.06%	Perf Quarter	26.79%
Income	-243.32M	P/S	121.91	EPS this Y	-2.67%	Inst Trans	2.40%	Short Ratio	6.51	Perf Half Y	420.32%
Sales	24.05M	P/B	8.01	EPS next Y	2.04%	ROA	-64.28%	Short Interest	11.23M	Perf YTD	136.17%
Book/sh	2.88	P/C	9.50	EPS next 5Y	11.70%	ROE	-86.68%	52W High	30.60 -24.67%	Perf Year	237.48%
Cash/sh	2.43	P/FCF	-	EPS past 3/5Y	-9.85% -	ROIC	-72.95%	52W Low	2.76 735.11%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	85.46%	Volatility	5.36% 7.70%	Perf 5Y	-
Dividend TTM	-	EV/Sales	110.61	EPS Y/Y TTM	45.01%	Oper. Margin	-1776.32%	ATR (14)	1.82	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.34	Sales Y/Y TTM	-	Profit Margin	-1011.75%	RSI (14)	45.59	Recom	1.09
Dividend Gr. 3/5Y	- -	Current Ratio	4.34	EPS Q/Q	49.04%	SMA20	-3.30%	Beta	-0.64	Target Price	38.40
Payout	-	Debt/Eq	0.12	Sales Q/Q	-	SMA50	-11.06%	Rel Volume	0.53	Prev Close	22.94
Employees	224	LT Debt/Eq	0.11	Earnings	Mar 19 AMC	SMA200	91.55%	Avg Volume	1.73M	Price	23.05
IPO	Jun 28, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.31% -18.36%	Trades		Volume	911,136	Change	0.48%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-26	Initiated	Raymond James	Strong Buy	$46
Feb-25-26	Initiated	Stifel	Buy	$44
Jan-21-26	Initiated	Chardan Capital Markets	Buy	$37
Jul-25-25	Initiated	Wells Fargo	Overweight	$17
Jun-10-25	Resumed	Guggenheim	Buy	$18
Jan-30-25	Initiated	Oppenheimer	Outperform	$32
Oct-31-24	Initiated	Robert W. Baird	Outperform	$25
Oct-17-24	Initiated	H.C. Wainwright	Buy	$30
Jul-23-24	Initiated	Morgan Stanley	Overweight	$36
Jul-23-24	Initiated	Leerink Partners	Outperform	$29
Jul-23-24	Initiated	Guggenheim	Buy	$32
Jul-23-24	Initiated	Cantor Fitzgerald	Overweight

Show Previous Ratings

Mar-28-26 01:30PM	Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis (GlobeNewswire)
Mar-19-26 04:05PM	Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements (GlobeNewswire)
Mar-18-26 08:00AM	Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-02-26 08:05AM	Alumis to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-26-26 08:10PM	Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference (MarketBeat)
11:42AM	Loading…
Feb-12-26 11:42AM	Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim Summit (MarketBeat)
Feb-05-26 08:05AM	Alumis to Participate in Upcoming February Investor Conferences (GlobeNewswire)
Jan-30-26 09:48AM	Chardan Highlights Alumis's (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials (Insider Monkey) -8.68%
Jan-19-26 08:45AM	Huge Insider Buying Now at This Insurance Giant and 2 Biotechs (24/7 Wall St.)
Jan-16-26 08:39PM	Staar Surgical, Alumis, and More Stocks See Action From Activist Investors (Barrons.com) +9.22%
Jan-15-26 04:12PM	David Vs. Goliath: Why Small Caps Are Crushing The Magnificent 7 (Benzinga)
11:35AM	HC Wainwright & Co. Hikes Alumis Inc. (ALMS)'s Price Target To $40 From $20, Reiterates Buy Rating (Insider Monkey)
Jan-09-26 04:05PM	Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +7.59% +7.82%
Jan-08-26 08:56AM	What's Going On With Alumis Stock Thursday? (Benzinga)
Jan-07-26 10:52PM	Alumis Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +10.41%
11:52AM	Loading…
11:52AM	ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies (Zacks)
11:35AM	Should You Chase the Rally in Alumis Stock Today? (Barchart)
Jan-06-26 05:30PM	Ventyx Biosciences Launches On Rumored $1 Billion Eli Lilly Takeover (Investor's Business Daily) +95.31%
04:29PM	Alumis Stock Catapults More Than 95% As Biotech Takes On J&J, Protagonist In Psoriasis (Investor's Business Daily)
04:12PM	Alumis Announces Proposed Public Offering of Common Stock (GlobeNewswire)
10:59AM	Alumis Stock Hits Record High on Psoriasis Drug Trial Results (Schaeffer's Research)
07:00AM	Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program (GlobeNewswire)
Jan-05-26 05:00PM	Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire) -7.20%
Nov-13-25 04:15PM	Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress (GlobeNewswire)
Nov-04-25 08:00AM	Alumis to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Aug-29-25 07:00AM	Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-25 04:05PM	Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-25 05:31PM	TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications \| DelveInsight (PR Newswire)
Jul-29-25 10:23AM	Alumis (ALMS) Merges with ACELYRIN (Insider Monkey)
Jul-24-25 07:30AM	Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus (GlobeNewswire)
04:05PM	Loading…
Jul-14-25 04:05PM	Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary (GlobeNewswire)
May-30-25 05:23AM	Alumis concludes enrolment in Phase III programme of plaque psoriasis therapy (Clinical Trials Arena) -10.49%
May-29-25 04:15PM	Alumis to Present at the Jefferies Global Healthcare Investor Conference (GlobeNewswire)
07:55AM	Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
May-21-25 09:10AM	Alumis Completes Merger with ACELYRIN (GlobeNewswire)
May-14-25 04:05PM	Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements (GlobeNewswire) +18.63%
May-13-25 01:00PM	Alumis Stockholders Approve Merger with ACELYRIN (GlobeNewswire) -15.05%
01:00PM	ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases (GlobeNewswire)
May-06-25 04:30PM	Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote FOR the Proposed Transaction with Alumis (GlobeNewswire) +10.11%
May-02-25 01:45PM	Acelyrin urges stockholders to vote for proposed merger with Alumis (TipRanks) +19.84%
May-01-25 01:30PM	ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis (GlobeNewswire) -7.49%
Apr-29-25 01:22PM	Acelyrin should liquidate instead of merging with Alumis, investor says (BioPharma Dive) +5.10%
Apr-21-25 06:30AM	Alumis and ACELYRIN Announce Amended Merger Agreement (GlobeNewswire) -6.00%
Apr-10-25 07:00AM	3 Biopharmaceutical Stocks Bucking the Sell-Off (MarketBeat) -15.05%
Apr-07-25 01:43PM	Alumis: Biotech's Stock Gains >100% In A Month - But Risk Of Failure Is High (Seeking Alpha)
Apr-04-25 04:34PM	Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger (GlobeNewswire) +17.68%
Mar-25-25 10:51AM	Alumis and Kaken sign agreement in Japan to develop ESK-001 (Pharmaceutical Technology) +5.96%
02:30AM	Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan (GlobeNewswire)
Mar-21-25 07:08AM	Why Alumis Inc. (ALMS) Went Down On Thursday? (InsiderMonkey) +5.04%
Mar-19-25 04:05PM	Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements (GlobeNewswire) -18.31%
Mar-10-25 08:00AM	Alumis to Present at Leerink's 2025 Global Healthcare Conference (GlobeNewswire)
Mar-08-25 09:00AM	Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis (GlobeNewswire)
Mar-04-25 09:01AM	Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire)
09:01AM	ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire)
09:00AM	ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger (GlobeNewswire)
Feb-28-25 09:08AM	Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout (GlobeNewswire)
Feb-27-25 04:15PM	Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases (GlobeNewswire)
Feb-20-25 09:00PM	ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences (GlobeNewswire)
Feb-10-25 04:45PM	Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) -14.99%
Feb-07-25 10:44AM	Alumis and Acelyrin sign merger agreement (Pharmaceutical Technology) -13.96%
03:00AM	Immune drugmakers Alumis and Acelyrin to merge (BioPharma Dive)
Feb-06-25 04:15PM	Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases (GlobeNewswire) -7.57%
Jan-30-25 02:48PM	Why Alumis (ALMS) Stock Is Advancing Today (Insider Monkey)
Jan-28-25 08:00AM	Alumis Strengthens Leadership Team with Key Appointments (GlobeNewswire)
Dec-19-24 08:00AM	Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 (GlobeNewswire)
Nov-14-24 04:05PM	Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 (GlobeNewswire) -12.95% -5.95%
Nov-13-24 04:05PM	Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements (GlobeNewswire)
Nov-04-24 08:00AM	Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
Sep-27-24 09:00AM	Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study (GlobeNewswire) -6.77%
Sep-03-24 04:29PM	Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-24 04:05PM	Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements (GlobeNewswire)
Jul-29-24 08:00AM	Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
Jun-27-24 11:57PM	Alumis Announces Pricing of Initial Public Offering (GlobeNewswire)

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AKKARAJU SRINIVAS	Director	Jan 09 '26	Buy	17.00	588,235	9,999,995	1,853,488	Jan 13 06:20 PM
Foresite Labs, LLC	10% Owner	Jan 08 '26	Buy	17.00	411,764	6,999,988	5,702,536	Jan 12 09:59 PM
Foresite Capital Management VI	10% Owner	Jan 08 '26	Buy	17.00	411,764	6,999,988	5,702,536	Jan 12 09:58 PM
Tananbaum James B.	Director	Jan 08 '26	Buy	17.00	411,764	6,999,988	5,702,536	Jan 12 09:58 PM
AKKARAJU SRINIVAS	Director	Dec 05 '25	Buy	9.84	186,377	1,833,760	1,265,253	Dec 09 07:13 PM
AKKARAJU SRINIVAS	Director	Dec 03 '25	Buy	7.75	100,000	775,000	1,012,849	Dec 04 08:11 PM
AKKARAJU SRINIVAS	Director	Dec 02 '25	Buy	7.55	96,000	724,800	912,849	Dec 04 08:11 PM
AKKARAJU SRINIVAS	Director	Dec 04 '25	Buy	8.18	66,027	540,101	1,078,876	Dec 04 08:11 PM
AKKARAJU SRINIVAS	Director	Dec 01 '25	Buy	7.46	86,350	644,171	816,849	Dec 01 06:09 PM
AKKARAJU SRINIVAS	Director	Nov 26 '25	Buy	7.64	48,537	370,823	691,797	Dec 01 06:09 PM
AKKARAJU SRINIVAS	Director	Nov 28 '25	Buy	7.64	38,702	295,683	730,499	Dec 01 06:09 PM
Foresite Capital Management VI	10% Owner	Nov 21 '25	Buy	7.38	72,212	532,925	2,614,215	Nov 25 04:02 PM
Tananbaum James B.	Director	Nov 21 '25	Buy	7.38	72,212	532,925	2,614,215	Nov 25 04:02 PM
Foresite Labs, LLC	10% Owner	Nov 21 '25	Buy	7.38	72,212	532,925	2,614,215	Nov 25 04:01 PM
AKKARAJU SRINIVAS	Director	Nov 20 '25	Buy	7.20	125,743	905,350	643,260	Nov 24 06:50 PM
Foresite Labs, LLC	10% Owner	Nov 19 '25	Buy	6.56	190,500	1,249,680	2,542,003	Nov 19 08:54 PM
Foresite Labs, LLC	10% Owner	Nov 17 '25	Buy	5.59	200,000	1,118,500	2,234,129	Nov 19 08:54 PM
Foresite Labs, LLC	10% Owner	Nov 18 '25	Buy	6.19	117,374	726,545	2,351,503	Nov 19 08:54 PM
Foresite Capital Management VI	10% Owner	Nov 19 '25	Buy	6.56	190,500	1,249,680	2,542,003	Nov 19 08:52 PM
Foresite Capital Management VI	10% Owner	Nov 17 '25	Buy	5.59	200,000	1,118,500	2,234,129	Nov 19 08:52 PM
Foresite Capital Management VI	10% Owner	Nov 18 '25	Buy	6.19	117,374	726,545	2,351,503	Nov 19 08:52 PM
Tananbaum James B.	Director	Nov 19 '25	Buy	6.56	190,500	1,249,680	2,542,003	Nov 19 08:51 PM
Tananbaum James B.	Director	Nov 17 '25	Buy	5.59	200,000	1,118,500	2,234,129	Nov 19 08:51 PM
Tananbaum James B.	Director	Nov 18 '25	Buy	6.19	117,374	726,545	2,351,503	Nov 19 08:51 PM
AKKARAJU SRINIVAS	Director	Nov 19 '25	Buy	6.56	137,772	903,784	517,517	Nov 19 08:46 PM
AKKARAJU SRINIVAS	Director	Nov 18 '25	Buy	6.05	102,652	621,045	379,745	Nov 19 08:46 PM
AKKARAJU SRINIVAS	Director	Nov 17 '25	Buy	5.51	914	5,036	277,093	Nov 19 08:46 PM
AKKARAJU SRINIVAS	Director	Nov 13 '25	Buy	5.25	276,179	1,449,940	276,179	Nov 17 04:59 PM
Tananbaum James B.	Director	May 02 '25	Buy	4.62	25,000	115,500	4,227,670	May 06 09:48 PM
Tananbaum James B.	Director	May 06 '25	Buy	4.34	20,000	86,800	4,247,670	May 06 09:48 PM
Foresite Labs, LLC	10% Owner	May 02 '25	Buy	4.62	25,000	115,500	4,227,670	May 06 09:48 PM
Foresite Labs, LLC	10% Owner	May 06 '25	Buy	4.34	20,000	86,800	4,247,670	May 06 09:48 PM
Foresite Capital Management VI	10% Owner	May 02 '25	Buy	4.62	25,000	115,500	4,227,670	May 06 09:47 PM
Foresite Capital Management VI	10% Owner	May 06 '25	Buy	4.34	20,000	86,800	4,247,670	May 06 09:47 PM
AKKARAJU SRINIVAS	Director	May 05 '25	Buy	4.67	160,370	749,676	3,586,788	May 06 06:52 PM
AKKARAJU SRINIVAS	Director	May 02 '25	Buy	4.55	159,920	727,636	3,426,418	May 06 06:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALMS

Alumis Inc

Upgrade your Finviz experience